Details of the Drug

General Information of Drug (ID: DM1PV4Y)

Drug Name
CS-600G
Synonyms
Koloxo; Loxoprofen; Loxoprofen (INN); Loxoprofen [INN]; Loxoprofen sodium hydrate; Loxoprofene; Loxoprofene [French]; Loxoprofeno; Loxoprofeno [Spanish]; Loxoprofenum; Loxoprofenum [Latin]; YMBXTVYHTMGZDW-UHFFFAOYSA-N; sodium loxoprofen; yl]-propionic acid; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; 68767-14-6; CHEBI:76172; CHEMBL19299; CS-600; MFCD00864331; Oxeno
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 246.3
Logarithm of the Partition Coefficient (xlogp) 2.4
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Bioavailability
The bioavailability of drug is 0.64% [1]
Elimination
50% of drug renal excretion, and 20% - 30% of drug is excreted in the stool [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [3]
Metabolism
The drug is metabolized via the carbonyl reductase in the liver [4]
Vd
The volume of distribution (Vd) of drug is 0.16 L/kg [3]
Chemical Identifiers
Formula
C15H18O3
IUPAC Name
2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
Canonical SMILES
CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
InChI
YMBXTVYHTMGZDW-UHFFFAOYSA-N
InChIKey
1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
Cross-matching ID
PubChem CID
3965
ChEBI ID
CHEBI:76172
CAS Number
68767-14-6
DrugBank ID
DB09212
INTEDE ID
DR0990

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Claudin-1 (CLDN1) OT27KV99 CLD1_HUMAN Gene/Protein Processing [6]
Claudin-3 (CLDN3) OT71MN9S CLD3_HUMAN Gene/Protein Processing [6]
Claudin-5 (CLDN5) OTUX60YO CLD5_HUMAN Gene/Protein Processing [6]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Gene/Protein Processing [7]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [6]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Post-Translational Modifications [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002.
2 LOXOPROFEN
3 Loxoprofen Sodium
4 Ravindran S, Zharikova OL, Hill RA, Nanovskaya TN, Hankins GD, Ahmed MS: Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol. 2006 Dec 15;72(12):1730-7. doi: 10.1016/j.bcp.2006.08.024. Epub 2006 Aug 30.
5 Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
6 Loxoprofen enhances intestinal barrier function via generation of its active metabolite by carbonyl reductase 1 in differentiated Caco-2?cells. Chem Biol Interact. 2021 Oct 1;348:109634. doi: 10.1016/j.cbi.2021.109634. Epub 2021 Sep 8.
7 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.